267425-71-8

Basic information

• Product Name: 2-Furancarboxylicacid,tetrahydro-2-(2-propenyl)-(9CI)
• Synonyms: 2-Furancarboxylicacid,tetrahydro-2-(2-propenyl)-(9CI);allyl tetrahydrofuran-2-carboxylate
• CAS NO: 267425-71-8
• Molecular Formula: C₈H₁₂O₃
• Molecular Weight: 156.17908
• Product Categories: CARBOXYLICACID
• Mol File: 267425-71-8.mol

Chemical Properties

• Boiling Point: 267.0±33.0 °C(Predicted)
• Appearance: /
• Density: 1.118±0.06 g/cm3(Predicted)
• PKA: 3.58±0.20(Predicted)
• CAS DataBase Reference: 2-Furancarboxylicacid,tetrahydro-2-(2-propenyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Furancarboxylicacid,tetrahydro-2-(2-propenyl)-(9CI)(267425-71-8)
• EPA Substance Registry System: 2-Furancarboxylicacid,tetrahydro-2-(2-propenyl)-(9CI)(267425-71-8)

Safety Data

• Hazardous Substances Data: 267425-71-8(Hazardous Substances Data)

Upstream product

• 83867-84-9 allyl ester of 2-tetrahydrofuroic acid 

Downstream Products

• 267425-72-9 (S)-2-(2-Oxo-ethyl)-tetrahydro-furan-2-carboxylic acid amide 

Relevant articles and documents

Palladium-Catalyzed Alkene Carboalkoxylation Reactions of Phenols and Alcohols for the Synthesis of Carbocycles

Intermolecular alkene difunctionalization reactions between terminal alkenes bearing a pendant aryl or alkenyl triflate electrophile and exogenous alcohol or phenol nucleophiles are described. These transformations afford substituted indanyl or alkylidene

Heterocycle amides as cell adhesion inhibitors

Compounds of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

Synthesis of (-)-dysiherbaine.

[reaction: see text] The first synthesis of (-)-dysiherbaine has been accomplished using intramolecular SN2 substitutions of a carbamate anion on an epoxide and an alkoxide on a secondary mesylate to efficiently construct the bicyclic skeleton stereospecifically from xylose. A general sequence has been developed to introduce an allyl group and convert it to the alanine side chain that should be useful for the construction of dysiherbaine analogues.